| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| ln Vivo |
Intrathecal (i.t.) administration of Boc1 (10 and 100 μg) significantly decreased paw withdrawal latency (PWL) and paw withdrawal threshold (PWT) in the ipsilateral hindpaw from 24 to 48 hours after CFA injection, indicating an aggravation of inflammatory pain. Boc1 (10 μg) also reversed the anti-nociceptive effect of Anxa1_(2-26) (20 μg μl⁻¹) when co-administered. [2]
Moreover, Boc1 (10 and 100 μg) down-regulated endogenous ANXA1 expression in the ipsilateral L4/5 dorsal root ganglia (DRGs) at 2 days after CFA injection. [2] |
|---|---|
| Animal Protocol |
Male Sprague-Dawley rats (250-300 g) were used. Boc1 was dissolved in dimethyl-sulphoxide (DMSO) and then diluted in saline (DMSO:saline 1:3, v/v). The drug was administered intrathecally (i.t.) via a catheter implanted between L5 and L6 vertebrae. The injection volume was 10 μl followed by 10 μl of saline for flushing. Doses of 1, 10, and 100 μg were used. Injections were performed at 12 and 1 hour before CFA injection. [2]
|
| References |
|
| Additional Infomation |
Boc1 is a formyl peptide receptor (FPR) antagonist. This study used Boc1 to investigate the analgesic effect of FPR2/ALX in mediating annexin 1 (ANXA1) in inflammatory pain. The results showed that endogenous ANXA1 exerts an analgesic effect through FPR2/ALX at the dorsal root ganglion level, and Boc1 can block this effect. [2]
|
| Molecular Formula |
C44H59N5O8
|
|---|---|
| Molecular Weight |
785.9680
|
| Exact Mass |
785.436
|
| CAS # |
148182-34-7
|
| PubChem CID |
132822
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.6
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
22
|
| Heavy Atom Count |
57
|
| Complexity |
1300
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O=C([C@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])N([H])C(=O)OC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=O)N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(=O)O[H])C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])=O)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O)C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H]
|
| InChi Key |
NGNZQSPFQJCBJQ-LTLCPEALSA-N
|
| InChi Code |
InChI=1S/C44H59N5O8/c1-28(2)23-33(46-41(53)36(26-31-19-13-9-14-20-31)49-43(56)57-44(5,6)7)38(50)47-35(25-30-17-11-8-12-18-30)40(52)45-34(24-29(3)4)39(51)48-37(42(54)55)27-32-21-15-10-16-22-32/h8-22,28-29,33-37H,23-27H2,1-7H3,(H,45,52)(H,46,53)(H,47,50)(H,48,51)(H,49,56)(H,54,55)/t33-,34-,35-,36-,37-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-4-methyl-2-[[(2S)-2-[[(2S)-4-methyl-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]amino]-3-phenylpropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~127.23 mM)
H2O : ~1 mg/mL (~1.27 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2723 mL | 6.3616 mL | 12.7231 mL | |
| 5 mM | 0.2545 mL | 1.2723 mL | 2.5446 mL | |
| 10 mM | 0.1272 mL | 0.6362 mL | 1.2723 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
